ArticleJACC. Advances2026
Diagnostic Performance of the Mayo ATTR-CM Score in Diverse Populations: Comparison With the AMY Score.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Mayo transthyretin amyloid cardiomyopathy (ATTR-CM) and AMY scores were developed to identify patients at risk for ATTR-CM. However, both were derived largely from White male cohorts with preserved ejection fraction (EF ≥40%) and their performance in more diverse populations is uncertain.
objectivesThe objective of the study was to validate and compare performance of the Mayo ATTR-CM and AMY scores across racially, ethnically, and sex-diverse populations, and across the EF spectrum.
methodsTwo complementary cohorts were evaluated: a Mayo Clinic cardiac amyloid radionuclide imaging referral cohort (n = 1,553; 449 [29%] ATTR-CM) and Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations (SCAN-MP), a prospective community-based study of Black or Caribbean Hispanic individuals (n = 646; 43 [6.6%] ATTR-CM). Scores were calculated as published. Discrimination was assessed using receiver operating characteristic-area under the curve (AUC), with comparisons performed using DeLong's nonparametric method.
resultsThe Mayo ATTR-CM score demonstrated superior discrimination in both cohorts (AUC: 0.86; 95% CI: 0.84-0.88 Mayo; AUC: 0.81; 95% CI: 0.75-0.87 SCAN-MP) compared with AMY (AUC: 0.67; 95% CI: 0.64-0.70 Mayo; AUC: 0.70; 95% CI: 0.62-0.78 SCAN-MP; DeLong P < 0.001 for both). Performance remained robust among individuals with EF <40% and among women. The AMY score showed lower sensitivity across cohorts. Among individuals exceeding score cutoffs, the probability of ATTR-CM ranged from ∼1 in 2 in the Mayo cohort to ∼1 in 6 in SCAN-MP.
conclusionsThe Mayo ATTR-CM score demonstrates strong, consistent performance across diverse populations, including women, Black, and Hispanic individuals, and those with reduced EF, and outperforms the AMY score. Its reliance on routinely available clinical and echocardiographic data supports automated implementation and may facilitate earlier detection of ATTR-CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.